You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTolmetin
Accession NumberDB00500  (APRD01268)
TypeSmall Molecule
GroupsApproved
DescriptionA non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. [PubChem]
Structure
Thumb
Synonyms
1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid
1-Methyl-5-P-toluoylpyrrole-2-acetic acid
5-(P-Toluoyl)-1-methylpyrrole-2-acetic acid
Tolmetin
Tolmetina
Tolmétine
Tolmetino
Tolmetinum
External Identifiers
  • McN 2559
  • McN 2559-21-98
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-tolmetin Capsules 400mgcapsule400 mgoralNovopharm Limited1994-12-312005-08-10Canada
Tolectin 200 Tab 200mgtablet245 mgoralMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1976-12-312002-08-02Canada
Tolectin 400 Cap 400mgcapsule400 mgoralMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1980-12-312002-08-02Canada
Tolectin Tab 600mgtablet600 mgoralJanssen Inc1987-12-312006-02-27Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tolmetin Sodiumcapsule400 mg/1oralTeva Pharmaceuticals USA Inc2012-07-26Not applicableUs
Tolmetin Sodiumtablet200 mg/1oralMutual Pharmaceutical Company, Inc.2009-09-04Not applicableUs
Tolmetin Sodiumtablet, film coated600 mg/1oralMylan Pharmaceuticals Inc.1994-08-30Not applicableUs
Tolmetin Sodiumcapsule400 mg/1oralMutual Pharmaceutical Company, Inc.2009-09-04Not applicableUs
Tolmetin Sodiumcapsule400 mg/1oralMylan Pharmaceuticals Inc.1993-05-27Not applicableUs
Tolmetin Sodiumtablet, film coated600 mg/1oralSTAT Rx USA LLC2009-11-02Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
TolectinTeva
Tolectin DSTeva
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Tolmetin sodium
64490-92-2
Thumb
  • InChI Key: QGUALMNFRILWRA-UHFFFAOYSA-M
  • Monoisotopic Mass: 279.087137994
  • Average Mass: 279.2663
DBSALT000496
Categories
UNIID8K2JPN18B
CAS number26171-23-3
WeightAverage: 257.2845
Monoisotopic: 257.105193351
Chemical FormulaC15H15NO3
InChI KeyInChIKey=UPSPUYADGBWSHF-UHFFFAOYSA-N
InChI
InChI=1S/C15H15NO3/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18/h3-8H,9H2,1-2H3,(H,17,18)
IUPAC Name
2-[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetic acid
SMILES
CN1C(CC(O)=O)=CC=C1C(=O)C1=CC=C(C)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as acetophenones. These are organic compounds containing the acetophenone structure.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassAcetophenones
Direct ParentAcetophenones
Alternative Parents
Substituents
  • Acetophenone
  • Aryl ketone
  • Benzoyl
  • Toluene
  • Substituted pyrrole
  • N-methylpyrrole
  • Heteroaromatic compound
  • Pyrrole
  • Ketone
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, including the treatment of acute flares long-term management. Also for treatment of juvenile rheumatoid arthritis.
PharmacodynamicsTolmetin is a nonsteroidal anti-inflammatory agent. Studies in animals have shown tolmetin to possess anti-inflammatory, analgesic and antipyretic activity. In the rat, tolmetin prevents the development of experimentally induced polyarthritis and also decreases established inflammation. In patients with either rheumatoid arthritis or osteaoarthritis, tolmetin is as effective as aspirin and indomethacin in controlling disease activity, but the frequency of the milder gastrointestinal adverse effects and tinnitus was less than in aspirin-treated patients, and the incidence of central nervous system adverse effects was less than in indomethacin-treated patients. In patients with juvenile rheumatoid arthritis, tolmetin is as effective as aspirin in controlling disease activity, with a similar incidence of adverse reactions. tolmetin has produced additional therapeutic benefit when added to a regimen of gold salts and, to a lesser extent, with corticosteroids. Tolmetin should not be used in conjunction with salicylates since greater benefit from the combination is not likely, but the potential for adverse reactions is increased.
Mechanism of actionThe mode of action of tolmetin is not known. However, studies in laboratory animals and man have demonstrated that the anti-inflammatory action of tolmetin is not due to pituitary-adrenal stimulation. Tolmetin inhibits prostaglandin synthetase in vitro and lowers the plasma level of prostaglandin E in man. This reduction in prostaglandin synthesis may be responsible for the anti-inflammatory action. Tolmetin does not appear to alter the course of the underlying disease in man.
Related Articles
AbsorptionRapidly and almost completely absorbed with peak plasma levels being reached within 30-60 minutes after an oral therapeutic dose.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Essentially all of the administered dose is recovered in the urine in 24 hours either as an inactive oxidative metabolite or as conjugates of tolmetin.

SubstrateEnzymesProduct
Tolmetin
Not Available
Tolmetin glucuronideDetails
Route of eliminationNot Available
Half lifeBiphasic elimination from the plasma consisting of a rapid phase with a half-life of one to 2 hours followed by a slower phase with a half-life of about 5 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Tolmetin Action PathwayDrug actionSMP00704
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9752
Blood Brain Barrier+0.8387
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.7277
P-glycoprotein inhibitor INon-inhibitor0.9062
P-glycoprotein inhibitor IINon-inhibitor0.9542
Renal organic cation transporterNon-inhibitor0.7999
CYP450 2C9 substrateNon-substrate0.7091
CYP450 2D6 substrateNon-substrate0.7867
CYP450 3A4 substrateNon-substrate0.6233
CYP450 1A2 substrateNon-inhibitor0.9159
CYP450 2C9 inhibitorNon-inhibitor0.9353
CYP450 2D6 inhibitorNon-inhibitor0.9449
CYP450 2C19 inhibitorNon-inhibitor0.9389
CYP450 3A4 inhibitorNon-inhibitor0.9563
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9346
Ames testNon AMES toxic0.8887
CarcinogenicityNon-carcinogens0.8992
BiodegradationReady biodegradable0.5
Rat acute toxicity2.9129 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9535
hERG inhibition (predictor II)Non-inhibitor0.9545
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
  • Actavis elizabeth llc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral400 mg
Tabletoral245 mg
Tabletoral600 mg
Capsuleoral400 mg/1
Tabletoral200 mg/1
Tablet, film coatedoral600 mg/1
Prices
Unit descriptionCostUnit
Tolectin 600 mg tablet2.43USD tablet
Tolmetin sodium 600 mg tablet2.06USD tablet
Tolmetin Sodium 400 mg capsule1.77USD capsule
Tolmetin sodium 200 mg tablet0.77USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point156 dec °CPhysProp
water solubility222 mg/LNot Available
logP2.79SANGSTER (1993)
pKa3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.131 mg/mLALOGPS
logP2.81ALOGPS
logP2.73ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)3.96ChemAxon
pKa (Strongest Basic)-7.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59.3 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity72.39 m3·mol-1ChemAxon
Polarizability27.67 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.07 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesM01AB03M02AA21
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (77.4 KB)
MSDSDownload (44.3 KB)
Interactions
Drug Interactions
Drug
AbciximabTolmetin may increase the anticoagulant activities of Abciximab.
AcebutololTolmetin may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Aceclofenac.
AcenocoumarolTolmetin may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Tolmetin.
Alendronic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Alendronic acid.
AliskirenTolmetin may decrease the antihypertensive activities of Aliskiren.
AlprenololTolmetin may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Tolmetin.
AmikacinTolmetin may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideTolmetin may decrease the antihypertensive activities of Amiloride.
AncrodTolmetin may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Antipyrine.
Antithrombin III humanTolmetin may increase the anticoagulant activities of Antithrombin III human.
ApixabanTolmetin may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Tolmetin is combined with Apremilast.
ArdeparinTolmetin may increase the anticoagulant activities of Ardeparin.
ArgatrobanTolmetin may increase the anticoagulant activities of Argatroban.
ArotinololTolmetin may decrease the antihypertensive activities of Arotinolol.
AtenololTolmetin may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tolmetin.
BalsalazideTolmetin may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tolmetin.
BecaplerminTolmetin may increase the anticoagulant activities of Becaplermin.
BefunololTolmetin may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Tolmetin.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tolmetin.
BenoxaprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Benoxaprofen.
BetaxololTolmetin may decrease the antihypertensive activities of Betaxolol.
BevantololTolmetin may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tolmetin.
BisoprololTolmetin may decrease the antihypertensive activities of Bisoprolol.
BivalirudinTolmetin may increase the anticoagulant activities of Bivalirudin.
BopindololTolmetin may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Bromfenac.
BufuralolTolmetin may decrease the antihypertensive activities of Bufuralol.
BumetanideTolmetin may decrease the diuretic activities of Bumetanide.
BupranololTolmetin may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tolmetin.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tolmetin.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Tolmetin.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tolmetin.
CarprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Carprofen.
CarteololTolmetin may decrease the antihypertensive activities of Carteolol.
CarvedilolTolmetin may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tolmetin.
CeliprololTolmetin may decrease the antihypertensive activities of Celiprolol.
CertoparinTolmetin may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Chloroquine.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tolmetin.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tolmetin.
CholestyramineCholestyramine can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tolmetin.
Citric AcidTolmetin may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Tolmetin.
ColesevelamColesevelam can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineTolmetin may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Tolmetin is combined with D-Limonene.
Dabigatran etexilateTolmetin may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinTolmetin may increase the anticoagulant activities of Dalteparin.
DanaparoidTolmetin may increase the anticoagulant activities of Danaparoid.
DaunorubicinTolmetin may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Tolmetin is combined with Deferasirox.
DesirudinTolmetin may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Tolmetin.
DextranTolmetin may increase the anticoagulant activities of Dextran.
Dextran 40Tolmetin may increase the anticoagulant activities of Dextran 40.
Dextran 70Tolmetin may increase the anticoagulant activities of Dextran 70.
Dextran 75Tolmetin may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Diclofenac.
DicoumarolTolmetin may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Tolmetin is combined with Diflunisal.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tolmetin.
DihydrostreptomycinTolmetin may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tolmetin.
DoxorubicinTolmetin may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneTolmetin may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Droxicam.
Edetic AcidTolmetin may increase the anticoagulant activities of Edetic Acid.
EdoxabanTolmetin may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Tolmetin.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tolmetin.
EnoxaparinTolmetin may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Tolmetin is combined with Epirizole.
EpirubicinTolmetin may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneTolmetin may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tolmetin.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tolmetin.
EsmololTolmetin may decrease the antihypertensive activities of Esmolol.
Etacrynic acidTolmetin may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Tolmetin.
Ethyl biscoumacetateTolmetin may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etoricoxib.
Evening primrose oilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Tolmetin is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Tolmetin.
FlunixinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Flurbiprofen.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tolmetin.
Fondaparinux sodiumTolmetin may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Tolmetin.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tolmetin.
FramycetinTolmetin may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideTolmetin may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Tolmetin.
GentamicinTolmetin may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Tolmetin is combined with Haloperidol.
HeparinTolmetin may increase the anticoagulant activities of Heparin.
HirulogTolmetin may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Tolmetin is combined with HMPL-004.
HydralazineTolmetin may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tolmetin.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tolmetin.
Hygromycin BTolmetin may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Tolmetin is combined with Icatibant.
IdarubicinTolmetin may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tolmetin.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tolmetin.
IndenololTolmetin may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tolmetin.
IndoprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tolmetin.
IsoxicamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Isoxicam.
KanamycinTolmetin may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tolmetin.
LabetalolTolmetin may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Leflunomide.
LepirudinTolmetin may increase the anticoagulant activities of Lepirudin.
LevobunololTolmetin may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tolmetin.
LithiumThe serum concentration of Lithium can be increased when it is combined with Tolmetin.
LornoxicamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Tolmetin.
LoxoprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tolmetin.
LumiracoxibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tolmetin.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Meloxicam.
MesalazineTolmetin may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tolmetin.
MetamizoleThe risk or severity of adverse effects can be increased when Tolmetin is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Tolmetin.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tolmetin.
MetipranololTolmetin may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tolmetin.
MetoprololTolmetin may decrease the antihypertensive activities of Metoprolol.
MetrizamideTolmetin may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tolmetin.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Tolmetin.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tolmetin.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Tolmetin.
NadololTolmetin may decrease the antihypertensive activities of Nadolol.
NadroparinTolmetin may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Tolmetin is combined with NCX 4016.
NeomycinTolmetin may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nepafenac.
NetilmicinTolmetin may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tolmetin.
OlopatadineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Olopatadine.
OlsalazineTolmetin may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tolmetin.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Tolmetin.
OrgoteinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Orgotein.
OtamixabanTolmetin may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Oxaprozin.
OxprenololTolmetin may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Parecoxib.
ParomomycinTolmetin may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololTolmetin may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateTolmetin may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Tolmetin.
PhenindioneTolmetin may increase the anticoagulant activities of Phenindione.
PhenprocoumonTolmetin may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Phenylbutazone.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tolmetin.
PindololTolmetin may decrease the antihypertensive activities of Pindolol.
PiretanideTolmetin may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Tolmetin is combined with Piroxicam.
PlicamycinTolmetin may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tolmetin.
PractololTolmetin may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Tolmetin.
ProbenecidThe serum concentration of Tolmetin can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Tolmetin is combined with Propacetamol.
PropranololTolmetin may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Tolmetin.
Protein CTolmetin may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeTolmetin may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Tolmetin is combined with PTC299.
PuromycinTolmetin may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Tolmetin.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tolmetin.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Tolmetin.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tolmetin.
ResveratrolThe risk or severity of adverse effects can be increased when Tolmetin is combined with Resveratrol.
ReviparinTolmetin may increase the anticoagulant activities of Reviparin.
RibostamycinTolmetin may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Risedronate.
RivaroxabanTolmetin may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Rofecoxib.
SalicylamideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tolmetin.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Tolmetin.
SeratrodastThe risk or severity of adverse effects can be increased when Tolmetin is combined with Seratrodast.
SotalolTolmetin may decrease the antihypertensive activities of Sotalol.
SpectinomycinTolmetin may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Tolmetin.
SpironolactoneTolmetin may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Tolmetin is combined with SRT501.
StreptomycinTolmetin may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinTolmetin may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineTolmetin may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tolmetin.
SulindacThe risk or severity of adverse effects can be increased when Tolmetin is combined with Sulindac.
SulodexideTolmetin may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Suprofen.
TacrolimusTolmetin may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Tolmetin.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tolmetin.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tolmetin.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Tolmetin.
TenofovirThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tolmetin.
TepoxalinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Tolmetin is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tiaprofenic acid.
TiludronateThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tiludronate.
TimololTolmetin may decrease the antihypertensive activities of Timolol.
TobramycinTolmetin may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tolfenamic Acid.
TorasemideTolmetin may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tolmetin.
TranilastThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tolmetin.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tolmetin.
TriamtereneTolmetin may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tolmetin.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Tolmetin is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Tolmetin is combined with Valdecoxib.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tolmetin.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Tolmetin.
WarfarinTolmetin may increase the anticoagulant activities of Warfarin.
XimelagatranTolmetin may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Tolmetin is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Tolmetin is combined with Zileuton.
Zoledronic acidThe risk or severity of adverse effects can be increased when Tolmetin is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Tolmetin is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Burdan F, Szumilo J, Klepacz R, Dudka J, Korobowicz A, Tokarska E, Cendrowska-Pinkosz M, Madej B, Klepacz L: Gastrointestinal and hepatic toxicity of selective and non-selective cyclooxygenase-2 inhibitors in pregnant and non-pregnant rats. Pharmacol Res. 2004 Nov;50(5):533-43. [PubMed:15458776 ]
  2. Capasso A, Sorrentino L: Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum. Eur J Pharmacol. 1997 Jul 9;330(2-3):199-204. [PubMed:9253954 ]
  3. Kirkova M, Alexandova A, Kesiova M, Todorov S: In vivo effects of amtolmetin guacyl on lipid peroxidation and antioxidant defence systems. Comparison with non-selective and COX-2 selective NSAIDs. Auton Autacoid Pharmacol. 2007 Apr;27(2):99-104. [PubMed:17391279 ]
  4. Kennedy JH, Korn N, Thurston RJ: Prostaglandin levels in seminal plasma and sperm extracts of the domestic turkey, and the effects of cyclooxygenase inhibitors on sperm mobility. Reprod Biol Endocrinol. 2003 Oct 9;1:74. [PubMed:14613550 ]
  5. Capasso A: Further studies on the involvement of the arachidonic acid cascade in the acute dependence produced by mu, kappa and delta opioid agonists in isolated tissues. Neuropharmacology. 1999 Jun;38(6):871-7. [PubMed:10465690 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Capasso A, Sorrentino L: Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum. Eur J Pharmacol. 1997 Jul 9;330(2-3):199-204. [PubMed:9253954 ]
  2. Kennedy JH, Korn N, Thurston RJ: Prostaglandin levels in seminal plasma and sperm extracts of the domestic turkey, and the effects of cyclooxygenase inhibitors on sperm mobility. Reprod Biol Endocrinol. 2003 Oct 9;1:74. [PubMed:14613550 ]
  3. Capasso A: Further studies on the involvement of the arachidonic acid cascade in the acute dependence produced by mu, kappa and delta opioid agonists in isolated tissues. Neuropharmacology. 1999 Jun;38(6):871-7. [PubMed:10465690 ]
  4. Burdan F, Szumilo J, Marzec B, Klepacz R, Dudka J: Skeletal developmental effects of selective and nonselective cyclooxygenase-2 inhibitors administered through organogenesis and fetogenesis in Wistar CRL:(WI)WUBR rats. Toxicology. 2005 Dec 15;216(2-3):204-23. Epub 2005 Sep 22. [PubMed:16182428 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Tryptophan 2,3-dioxygenase activity
Specific Function:
Incorporates oxygen into the indole moiety of tryptophan. Has a broad specificity towards tryptamine and derivatives including D- and L-tryptophan, 5-hydroxytryptophan and serotonin (By similarity).
Gene Name:
TDO2
Uniprot ID:
P48775
Molecular Weight:
47871.215 Da
References
  1. Dairam A, Antunes EM, Saravanan KS, Daya S: Non-steroidal anti-inflammatory agents, tolmetin and sulindac, inhibit liver tryptophan 2,3-dioxygenase activity and alter brain neurotransmitter levels. Life Sci. 2006 Nov 10;79(24):2269-74. Epub 2006 Aug 1. [PubMed:16952380 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Peroxidase activity
Specific Function:
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
Gene Name:
MPO
Uniprot ID:
P05164
Molecular Weight:
83867.71 Da
References
  1. Anderson R, Oosthuizen R, Grabow G: Prevention of peroxidase mediated inhibition of neutrophil motility and lymphocyte transformation by levamisole, OMPI, sodium aurothiomalate, indomethacin and tolmetin in vitro. Int J Immunopharmacol. 1981;3(2):123-32. [PubMed:6266970 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23